212 related articles for article (PubMed ID: 12653579)
1. The relationship between p63 and p53 expression in normal and neoplastic breast tissue.
Ribeiro-Silva A; Zambelli Ramalho LN; Britto Garcia S; Zucoloto S
Arch Pathol Lab Med; 2003 Mar; 127(3):336-40. PubMed ID: 12653579
[TBL] [Abstract][Full Text] [Related]
2. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.
Barbareschi M; Pecciarini L; Cangi MG; Macrì E; Rizzo A; Viale G; Doglioni C
Am J Surg Pathol; 2001 Aug; 25(8):1054-60. PubMed ID: 11474290
[TBL] [Abstract][Full Text] [Related]
3. p63 expression in benign and malignant breast lesions.
Stefanou D; Batistatou A; Nonni A; Arkoumani E; Agnantis NJ
Histol Histopathol; 2004 Apr; 19(2):465-71. PubMed ID: 15024707
[TBL] [Abstract][Full Text] [Related]
4. Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?
Ribeiro-Silva A; Ramalho LN; Garcia SB; Zucoloto S
Braz J Med Biol Res; 2004 Jan; 37(1):89-95. PubMed ID: 14689049
[TBL] [Abstract][Full Text] [Related]
5. P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.
Preto A; Reis-Filho JS; Ricardo S; Soares P
Pathol Res Pract; 2002; 198(7):449-54. PubMed ID: 12234063
[TBL] [Abstract][Full Text] [Related]
6. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
8. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Ribeiro-Silva A; Ramalho LN; Garcia SB; Brandão DF; Chahud F; Zucoloto S
Histopathology; 2005 Nov; 47(5):458-66. PubMed ID: 16241993
[TBL] [Abstract][Full Text] [Related]
9. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
[TBL] [Abstract][Full Text] [Related]
10. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray.
Reis-Filho JS; Simpson PT; Martins A; Preto A; Gärtner F; Schmitt FC
Virchows Arch; 2003 Aug; 443(2):122-32. PubMed ID: 12884041
[TBL] [Abstract][Full Text] [Related]
11. P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63?
Faridoni-Laurens L; Bosq J; Janot F; Vayssade M; Le Bihan ML; Kaghad M; Caput D; Bénard J; Ahomadegbe JC
Oncogene; 2001 Aug; 20(38):5302-12. PubMed ID: 11536043
[TBL] [Abstract][Full Text] [Related]
12. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast?
Ribeiro-Silva A; Zamzelli Ramalho LN; Garcia SB; Zucoloto S
Pathol Oncol Res; 2003; 9(1):20-3. PubMed ID: 12704442
[TBL] [Abstract][Full Text] [Related]
13. p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?
de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Alvarenga M; Vassallo J
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):71-7. PubMed ID: 16540734
[TBL] [Abstract][Full Text] [Related]
14. p63 expression in normal skin and usual cutaneous carcinomas.
Reis-Filho JS; Torio B; Albergaria A; Schmitt FC
J Cutan Pathol; 2002 Oct; 29(9):517-23. PubMed ID: 12358808
[TBL] [Abstract][Full Text] [Related]
15. p63 expression is associated with high histological grade, aberrant p53 expression and TP53 mutation in HER2-positive breast carcinoma.
Guo S; Wang Y; Rohr J; Shang L; Ma J
J Clin Pathol; 2021 Oct; 74(10):641-645. PubMed ID: 32873702
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Livasy CA; Karaca G; Nanda R; Tretiakova MS; Olopade OI; Moore DT; Perou CM
Mod Pathol; 2006 Feb; 19(2):264-71. PubMed ID: 16341146
[TBL] [Abstract][Full Text] [Related]
17. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma.
Koker MM; Kleer CG
Am J Surg Pathol; 2004 Nov; 28(11):1506-12. PubMed ID: 15489655
[TBL] [Abstract][Full Text] [Related]
18. p63 expression in normal, hyperplastic and malignant breast tissues.
Wang X; Mori I; Tang W; Nakamura M; Nakamura Y; Sato M; Sakurai T; Kakudo K
Breast Cancer; 2002; 9(3):216-9. PubMed ID: 12185332
[TBL] [Abstract][Full Text] [Related]
19. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
[TBL] [Abstract][Full Text] [Related]
20. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast.
Reis-Filho JS; Milanezi F; Paredes J; Silva P; Pereira EM; Maeda SA; de Carvalho LV; Schmitt FC
Appl Immunohistochem Mol Morphol; 2003 Mar; 11(1):1-8. PubMed ID: 12610349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
